ArticleDrugs - real world outcomes2026
Prospective Real-World Assessment of Pain Relief with Injection-Based Delivery of Etoricoxib (RAPID Study).
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pain is frequently inadequately controlled in routine clinical practice, particularly when oral analgesic administration is delayed or impractical. Intramuscular (IM) etoricoxib offers a parenteral option for rapid pain control; however, prospective real-world evidence across diverse acute pain conditions remains limited.
objectivesThe primary objective was to evaluate changes in pain intensity using the Numeric Pain Rating Scale (NPRS) from baseline to predefined post-injection timepoints. Secondary objectives included physician global assessment of pain relief and assessment of tolerability based on reported adverse events. The findings are expected to further strengthen the clinical evidence base for intramuscular (IM) etoricoxib and inform its integration into acute pain management pathways in Indian healthcare settings.
methodsThis multicenter, noncomparative, prospective observational study was conducted across 68 sites in India. Adults with acute painful conditions prescribed Nucoxia® 90 mg IM etoricoxib as part of routine care were enrolled. Pain intensity was assessed using the Numeric Pain Rating Scale (NPRS) at baseline and predefined post-injection timepoints. The primary endpoint was change in NPRS score from baseline to 60 min post-injection. Effectiveness was additionally evaluated using the Global Physician Assessment. Safety outcomes included injection-site reactions and adverse events.
resultsA total of 418 patients were included (364 inpatients; 54 outpatients), with a mean age of 46.0 ± 10.9 years; 69.6% (291/418) were male. Low back pain (36.1%) was the most common indication. Among inpatients, mean NPRS scores decreased from 7.6 ± 1.5 at baseline to 3.3 ± 2.3 at 60 min (p < 0.001), with sustained improvement to 0.3 at 24 h; 88.7% (323/364) were pain free at 24 h. Among outpatients, mean NPRS scores declined from 6.1 ± 1.6 to 0.8 ± 1.5 at 60 min, with 70.4% (38/54) reporting complete pain relief (p < 0.001). Physicians reported marked or moderate improvement in 82.3% (344/418) of patients. Adverse events were infrequent, reported by 2.5% of patients with available safety data (9/360).
conclusionsIM etoricoxib was associated with rapid and sustained pain reduction and demonstrated a favorable tolerability profile across a range of acute pain conditions in Indian clinical practice.
Identifiers
42631828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.